Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 2/20 | 0.76 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.76 |
| ▸ | NPC1 | O15118 | 6/20 | 0.50 |
| ▸ | RAB9A | P51151 | 5/20 | 0.50 |
| ▸ | NAMPT | P43490 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | F2 | P00734 | 1/20 | 0.43 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.42 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.42 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13964828 | 0.89 | HDAC1 (0.61) | HDAC1HDAC6NPC1RAB9AMEN1 | |
| SCHEMBL4065365 | 0.85 | HDAC1 (0.74) | HDAC1HDAC6NPC1RAB9ANAMPT | |
| SCHEMBL4066161 | 0.84 | HDAC1 (0.63) | HDAC1HDAC6NPC1RAB9ACXCR4 | |
| SCHEMBL4895365 | 0.83 | HDAC1 (0.74) | HDAC1HDAC6CXCR4KDM4EALDH1A1 | |
| Bromide SCHEMBL5140296 | 0.83 | HDAC1 (0.62) | HDAC1HDAC6NPC1RAB9ACXCR4 | |
| SCHEMBL4065804 | 0.83 | HDAC1 (0.78) | HDAC1HDAC6CXCR4KDM4EALDH1A1 | |
| SCHEMBL13964724 | 0.83 | HDAC1 (0.68) | HDAC1HDAC6NPC1RAB9AKMT2A | |
| SCHEMBL4061554 | 0.82 | HDAC1 (0.70) | HDAC1HDAC6RAB9AKMT2ACXCR4 | |
| SCHEMBL13909820 | 0.82 | HDAC1 (0.76) | HDAC1HDAC6CXCR4KDM4EALDH1A1 | |
| SCHEMBL4562865 | 0.80 | HDAC1 (0.69) | HDAC1HDAC6CXCR4KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080090846-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | GENZYME CORPORATION | 2008-04-17 | — | — | US | claimed |
| EP-1317443-B1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC (CA) | 2009-01-14 | — | — | EP | disclosed |
| EP-1317443-B1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC (CA) | 2009-01-14 | — | — | EP | disclosed |
| US-20080090846-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | GENZYME CORPORATION | 2008-04-17 | — | — | US | disclosed |
| US-20080090846-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | GENZYME CORPORATION | 2008-04-17 | — | — | US | disclosed |
| US-20080090846-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | GENZYME CORPORATION | 2008-04-17 | — | — | US | disclosed |
| US-7312234-B2 | Chemokine receptor binding heterocyclic compounds | ANORMED (CA) | 2007-12-25 | — | — | US | disclosed |
| US-7312234-B2 | Chemokine receptor binding heterocyclic compounds | ANORMED (CA) | 2007-12-25 | — | — | US | disclosed |
| US-7312234-B2 | Chemokine receptor binding heterocyclic compounds | ANORMED (CA) | 2007-12-25 | — | — | US | disclosed |
| US-20050026942-A1 | Chemokine receptor binding heterocyclic compounds | ANORMED (CA) | 2005-02-03 | — | — | US | disclosed |
| US-6835731-B2 | Viricides; antiinflammatory agents; antiallergens; antiarthritic agents | ANORMED, INC. (CA) | 2004-12-28 | — | — | US | disclosed |
| EP-1317443-A2 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC. (CA) | 2003-06-11 | — | — | EP | disclosed |
| US-20020147192-A1 | Chemokine receptor binding heterocyclic compounds | GENZYME CORPORATION | 2002-10-10 | — | — | US | disclosed |
| WO-2002022599-A2 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC. (CA) | 2002-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020147192-A1 | Chemokine receptor binding heterocyclic compounds | CCR2, CXCR3, ACKR3 | HDAC1 1482/4885HDAC6 1162/4885NPC1 1735/4885 |
| US-20080090846-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | CCR2, CXCR3, ACKR3 | HDAC1 1482/4885HDAC6 1162/4885NPC1 1735/4885 |
| US-20050026942-A1 | Chemokine receptor binding heterocyclic compounds | CCR2, CXCR3, ACKR3 | HDAC1 1482/4885HDAC6 1162/4885NPC1 1735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.